HJ-004-02 tablet for EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC).
- Your cancer has an EGFR mutation (a change in the EGFR gene) that was found by a tumor test.
- You have already tried standard treatments for your lung cancer and they either stopped working, caused intolerable side effects, or were not appropriate for you.
- You are generally well enough to be up and about (ECOG performance status 0 or 1).
- You have provided tumor tissue slides from a previous biopsy or surgery for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
This trial tests a new drug called JH021 in people with advanced solid tumors or a specific type of lung cancer. The goal is to see if it can help when other treatments have stopped working.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.